“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial of IMRT to treat bone and soft tissue sarcoma (IMRiS)
Coronavirus and cancer
We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
IMRT is a type of radiotherapy called intensity modulated radiotherapy, doctors want to see if it is a useful treatment for sarcoma and reduces side effects. Cancer Research UK supports this trial.
More about this trial
Doctors might give radiotherapy
- before surgery to shrink the cancer before removing it
- after surgery to reduce the risk of the cancer coming back
- to treat the cancer if it can’t be removed because of its position in the body
Intensity modulated radiotherapy (IMRT) matches the radiotherapy beams to the shape of the cancer. This reduces the amount of radiotherapy to the healthy tissue surrounding the cancer. This should lead to fewer side effects.
Some hospitals have used IMRT to treat bone and soft tissue sarcoma. But it hasn’t been properly tested to show if there is a benefit from treating these cancers with IMRT.
The aims of this trial are
- to see if IMRT reduces side effects, particularly long term effects
- to see if people with sarcoma are able to have the best dose of radiotherapy without causing damage to surrounding tissue
Who can enter
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
You may be able to join this trial if you are in one of the following situations. You have
- Soft tissue sarcoma of the arm or leg
- Ewing’s sarcoma that started in the pelvis or spine
- Bone sarcoma such as an osteosarcoma or a chondrosarcoma that is high grade in the pelvis and spine
- Chordoma in the pelvis or spine
- Are to have radiotherapy as part of your treatment
- Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
- Are willing to use reliable contraception during treatment and for 3 months afterwards if you or your partner could become pregnant
- Are at least 16 years old
You cannot join this trial if any of these apply. You
- Have a type of sarcoma called paediatric alveolar or embryonal rhabdomyosarcoma
- Are able to have proton beam radiotherapy if this is felt to be best for your tumour
- Have already had radiotherapy to the area where your cancer is
- Are having chemotherapy with radiotherapy (chemoradiation)
- Have, or have had, another cancer
- Are pregnant
This is a phase 2 trial. The researchers need 188 people to join.
Everyone will have intensity modulated radiotherapy (IMRT). Before you start IMRT you have a session to plan your radiotherapy.
You have IMRT once a day Monday to Friday for 5 to 7 weeks. How long depends on what type of sarcoma you have.
You see the doctor to have some tests before taking part. These tests include
During radiotherapy you see the doctor or nurse every week to see how you are.
You then see the doctor
- Every month for 3 months
- Every 3 months up to 3 years
Depending on the type of sarcoma you have another 1 or 2 scans after finishing radiotherapy.
The most common side effects of radiotherapy are
- hair loss only in the area being treated
- redness, flaking or peeling of the skin at the treated area
- inflammation and swelling at the treatment area
- feeling sick
- diarrhoea if the bowel is in the treatment area
- problem with wound healing if you have had surgery as part of your treatment
We have information on the side effects of radiotherapy.
How to join a clinical trial
Dr Beatrice Seddon
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
University College London (UCL)
This is Cancer Research UK trial number CRUK/14/015.